Used in the treatment of hemophilia A and B to prevent bleeding episodes by inhibiting tissue factor pathway inhibitor (TFPI), thereby enhancing thrombin generation and promoting clot formation. It functions as a long-acting subcutaneous therapy, offering a prophylactic option for patients with or without inhibitors to factor VIII or IX. Its mechanism supports sustained hemostasis with once-weekly dosing, improving patient compliance and quality of life.